Multiple Myeloma

Midwest CEPAC

Multiple myeloma (MM) is a blood cancer in which the bone marrow produces an overabundance of malignant plasma cells that emerge into the bloodstream. Ultimately, the proliferation of plasma cells can cause bone damage, anemia, low white blood cell counts, and kidney failure.  Approximately 25,000 cases of MM are diagnosed in the U.S. annually, with three quarters of affected individuals over 70 years of age. There is no cure for multiple myeloma, but its progression can be relatively slow in many individuals, often involving multiple rounds of remission after treatment followed by a subsequent relapse. Recent advances in therapy have greatly improved the disease’s prognosis.

Interventions of interest:

Carfilzomib (Kyprolis®, Onyx) with lenalidomide (Revlimid®, Celgene) and dexamethasone
Daratumumab (Darzalex®, Janssen Biotech) monotherapy
Elotuzumab (Empliciti®, Bristol Myers-Squibb) with lenalidomide and dexamethasone
Ixazomib (Ninlaro®, Takeda) with lenalidomide and dexamethasone
Panobinostat (Farydak®, Novartis Pharmaceuticals Corp.) with bortezomib (Velcade®, Takeda Millennium) and dexamethasone
Pomalidomide (Pomalyst®, Celgene) with low-dose dexamethasone

Date of review: May 2016

For questions or additional information, please contact info@icer-review.org

Associated Meetings

At its inaugural meeting, the Midwest CEPAC convened to discuss the comparative clinical effectiveness and value of therapies for multiple myeloma.


Key Dates

Associated Materials

02/05/2016

03/08/2016

03/08/2016

03/08/2016

04/07/2016

04/07/2016

05/06/2016

05/06/2016

05/06/2016

Public comments received on ICER’s Draft Evidence Report


05/06/2016

A summary of comments received on ICER’s report on treatments for multiple myeloma, and ICER’s response to comments.